Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

In the event of a dog bite, a person needs more than just the rabies vaccine. Experts highlight the importance of ...

March is a significant month for women's health, observing International Women's Day and National Women's HIV/AIDS Awareness ...

Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

Utilizing syringe service programs to provide comprehensive PrEP care shows promise for encouraging more people who inject ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

The new study, published in The Lancet, is the first to evaluate a once-yearly injection of an HIV pre-exposure prophylaxis ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...